TY  - CHAP
M1  - Book, Section
TI  - Chapter 1. Breast Carcinogenesis
A1  - van Diest, Paul J.
A1  - Buerger, Horst
A1  - Kuijper, Arno
A1  - van der Wall, Elsken
A2  - Kuerer, Henry M.
PY  - 2010
T2  - Kuerer's Breast Surgical Oncology
AB  - Breast  cancer  is  an  important  health  care  problem  since  it  is  the  most  frequently  occurring  cancer  (1  out  of  about  10  women)  and  among  the  major  causes  of  death  in  women  in  the  Western  world.  Despite  many  studies,  breast  carcinogenesis  is  still  not  well  understood.  Although  many  breast  cancer  risk  factors  have  been  identified,  they  do  not  easily  translate  into  molecular  changes  that  help  to  understand  why  normal  breast  cells  derail  to  form  early  lesions  that  then  accumulate  further  genetic  events  that  make  them  eventually  progress  to  cancer.  Discussing  these  risk  factors  is  therefore  beyond  the  scope  of  this  chapter.  We  will  also  stay  away  from  providing  endless  lists  of  possibly  relevant  individual  genetic  aberrations.  Rather,  we  will  try  to  integrate  the  fairly  fragmentary  knowledge  of  genetic  aberrations  and  changes  in  gene  expression  into  progression  models  based  on  long-standing  morphologic  progression  models.  This  is  quite  challenging,  since  breast  cancer  is  a  very  heterogeneous  disease,  far  beyond  the  so-called  ductal  and  lobular  lesions  that  are  best  known.  Nevertheless,  these  morphologic  progression  models  have  proven  to  provide  a  proper  framework  to  depict  and  understand  how  different  early  lesions  may  progress  to  cancer,  and  help  to  place  relevant  genetic  changes  into  the  different  progression  routes  to  cancer.  Further,  they  have  been  proven  to  be  clinically  relevant,  in  the  sense  that  relative  risk  of  these  lesions  to  progress  to  cancer  is  known  from  long-term  follow-up  studies.  This  has  become  the  base  for  clinical  management  of  such  lesions  when  found  in  a  breast  biopsy,  for  example,  after  a  mammographic  abnormality  on  breast  screening.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesssurgery.mhmedical.com/content.aspx?aid=6405001
ER  -